预约演示
更新于：2025-03-23
Toripalimab
特瑞普利单抗
更新于：2025-03-23
概要
基本信息
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 中国 (2018-12-17), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (美国)、突破性疗法 (美国)、快速通道 (美国)、孤儿药 (美国)、孤儿药 (欧盟)、优先审评 (中国)、附条件批准 (中国)、孤儿药 (澳大利亚)、优先审评 (新加坡) |
登录后查看时间轴
结构/序列
Sequence Code 453640391L
来源: *****
Sequence Code 524455911H
来源: *****
关联
522
项与 特瑞普利单抗 相关的临床试验NCT06682780
An Open-label, Dose-escalation, and Dose-expansion Phase I/II Clinical Study of Safety, Tolerability, Pharmacokinetic Profile, and Initial Efficacy of LM-2417 for Injection Alone or in Combination With Other Antitumor Agents in Patients With Advanced Solid Tumors
NCT06868199
A Phase I/II, First-in-Human (FIH), Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LM-168 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours
NCT06873854
Evaluation of a Phase II, Single-arm, Multicenter, Open-label Clinical Study on LM-108 Injection in Combination With Toripalimab for Advanced Malignant Solid Tumors in Patients With Unresectable or Metastatic Microsatellite Highly Unstable (MSI H) or Mismatch Repair Defects (dMMR) Who Have Failed Previous Treatment With Anti-PD-1/PD-L1 Drugs
100 项与 特瑞普利单抗 相关的临床结果
登录后查看更多信息
100 项与 特瑞普利单抗 相关的转化医学
登录后查看更多信息
100 项与 特瑞普利单抗 相关的专利（医药）
登录后查看更多信息
4,271
项与 特瑞普利单抗 相关的文献（医药）2025-12-31OncoImmunology
The immune checkpoint LAG-3 is expressed by melanoma cells and correlates with clinical progression of the melanoma
Article
作者: Richter, Jasmin ; Halama, Niels ; Eurich, Rosa ; Hassel, Jessica C ; Wiecken, Melanie ; Pfarr, Nicole ; Lenoir, Bénédicte ; Mayr, Eva-Maria ; Chakraborty, Shounak ; Machiraju, Devayani
Immune checkpoint blockers have substantially improved prognosis of melanoma patients, nevertheless, resistance remains a significant problem. Here, intrinsic and extrinsic factors in the tumor microenvironment are discussed, including the expression of alternative immune checkpoints such as lymphocyte activation gene 3 (LAG-3) and T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3). While most studies focus on immune cell expression of these proteins, we investigated their melanoma cell intrinsic expression by immunohistochemistry in melanoma metastases of 60 patients treated with anti-programmed cell death protein 1 (PD-1) and/or anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) therapy, and correlated it with the expression of potential ligands, RNA sequencing data and clinical outcome. LAG-3 and TIM-3 were commonly expressed in melanoma cells. In the stage IV cohort, expression of LAG-3 was associated with M1 stage (p < 0.001) and previous exposure to immune checkpoint inhibitors (p = 0.029). Moreover, in the anti-PD-1 monotherapy treatment group patients with high LAG-3 expression by tumor cells tended to have a shorter progression-free survival (p = 0.088), whereas high expression of TIM-3 was associated with a significantly longer overall survival (p = 0.007). In conclusion, we provide a systematic analysis of melanoma cell intrinsic LAG-3 and TIM-3 expression, highlighting potential implications of their expression on patient survival.
2025-12-31Hematology
Sintilimab for treating progressive multifocal leukoencephalopathy caused by human polyomavirus 2 virus infection following allogeneic hematopoietic cell transplantation: a case report
Article
作者: Zhong, Xushu ; Liu, Qinyu ; Jin, Xuelian ; Chen, Xinchuan
BACKGROUND:
Progressive multifocal leukoencephalopathy (PML) is characterized by demyelination in the central nervous system. It is caused by infection with human polyomavirus 2 and has a poor prognosis. Therapeutic strategies involve restoring immune function and/or discontinuing immunosuppressive treatment. Immune checkpoint inhibitors such as those targeting programmed death receptor-1 (PD-1) can alleviate PML by restoring T cell function. There are no case reports on the use of the PD-1 inhibitor, Sintilimab, for treating PML. Here, we report a case of successful treatment of PML with sintilimab following allogeneic hematopoietic stem cell transplantation.
CASE PRESENTATION:
A 35-year-old woman with high-risk acute myeloid leukemia underwent allogeneic hematopoietic stem cell transplantation after induced remission and developed PML 12 months after transplantation. She received five courses of 100 mg every 4 weeks with monitoring by magnetic resonance imaging (MRI) and viral load in the cerebrospinal fluid, showing clinical improvement, resolution of neurological symptoms, and reduced viral load. MRI showed initial exacerbation of lesions but significant improvement after five courses of treatment. No graft-versus-host disease occurred, but manageable immune reconstitution inflammatory syndrome was observed.
CONCLUSION:
Sintilimab, a PD-1 inhibitor, might be used to treat PML in patients with hematologic malignancies undergoing allo-HSCT, which needs further investigation.
2025-05-01SEMINARS IN CANCER BIOLOGY
Role of ubiquitination-driven metabolisms in oncogenesis and cancer therapy
Review
作者: Huang, Linlin ; Song, Chunhua ; Yang, Can ; Guan, Ming ; Yang, Dongqin
Ubiquitination represents one of the most critical post-translational modifications, comprising a multi-stage enzyme process that plays a pivotal role in a myriad of cellular biological activities. The deregulation of the processes of ubiquitination and deubiquitination is associated with the development of cancers and other diseases. This typescript reviews the impact of ubiquitination on metabolic processes, elucidating the regulatory functions of ubiquitination on pivotal enzymes within metabolic pathways in pathological contexts. It underscores the role of ubiquitination-driven metabolism disorders in the etiology of cancers, and oncogenesis, and highlights the potential therapeutic efficacy of targeting ubiquitination-driven enzymes in cancer metabolism, their combination with immune checkpoint inhibitors, and their clinical applications.
100 项与 特瑞普利单抗 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 晚期肝细胞癌 | 中国 | 2025-03-18 | |
| 转移性食管鳞状细胞癌 | 欧盟 | 2024-09-19 | |
| 转移性食管鳞状细胞癌 | 冰岛 | 2024-09-19 | |
| 转移性食管鳞状细胞癌 | 列支敦士登 | 2024-09-19 | |
| 转移性食管鳞状细胞癌 | 挪威 | 2024-09-19 | |
| 鼻咽肿瘤 | 欧盟 | 2024-09-19 | |
| 鼻咽肿瘤 | 冰岛 | 2024-09-19 | |
| 鼻咽肿瘤 | 列支敦士登 | 2024-09-19 | |
| 鼻咽肿瘤 | 挪威 | 2024-09-19 | |
| 复发性食管鳞状细胞癌 | 欧盟 | 2024-09-19 | |
| 复发性食管鳞状细胞癌 | 冰岛 | 2024-09-19 | |
| 复发性食管鳞状细胞癌 | 列支敦士登 | 2024-09-19 | |
| 复发性食管鳞状细胞癌 | 挪威 | 2024-09-19 | |
| 不能切除的食管鳞状细胞癌 | 欧盟 | 2024-09-19 | |
| 不能切除的食管鳞状细胞癌 | 冰岛 | 2024-09-19 | |
| 不能切除的食管鳞状细胞癌 | 列支敦士登 | 2024-09-19 | |
| 不能切除的食管鳞状细胞癌 | 挪威 | 2024-09-19 | |
| 三阴性乳腺癌 | 中国 | 2024-06-18 | |
| 广泛期小细胞肺癌 | 中国 | 2024-06-04 | |
| 转移性肾细胞癌 | 中国 | 2024-04-02 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 肿瘤 | 申请上市 | 加拿大 | 2024-12-01 | |
| 转移性黑色素瘤 | 申请上市 | 中国 | 2024-08-12 | |
| 不可切除的黑色素瘤 | 申请上市 | 中国 | 2024-08-12 | |
| 复发性鼻咽癌 | 申请上市 | 欧盟 | 2022-11-14 | |
| 复发性非鳞状非小细胞肺癌 | 临床3期 | 中国 | 2024-07-11 | |
| 局限期小细胞肺癌 | 临床3期 | 美国 | 2023-11-15 | |
| 局限期小细胞肺癌 | 临床3期 | 中国 | 2023-11-15 | |
| 局限期小细胞肺癌 | 临床3期 | 比利时 | 2023-11-15 | |
| 局限期小细胞肺癌 | 临床3期 | 法国 | 2023-11-15 | |
| 局限期小细胞肺癌 | 临床3期 | 格鲁吉亚 | 2023-11-15 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 胸腺上皮肿瘤 一线 | 维持 | 24 | 憲憲夢選網繭膚餘鑰糧(夢淵繭選廠齋壓鏇廠鹹) = 簾構鑰餘衊顧獵網醖蓋 蓋襯鹽淵廠鏇憲繭齋築 (膚網壓廠觸簾鏇簾蓋鹽, 14.0 ~ 32.0) 更多 | 积极 | 2025-03-21 | ||
ASCO_GU2025 人工标引  | N/A | 28 | 鏇窪獵鬱憲鬱窪獵壓觸(餘鬱鏇艱顧壓醖膚鹹衊) = 範糧築淵構顧選糧襯襯 糧顧選夢網鹽遞築製積 (願鬱鏇構選窪範襯簾觸 ) 更多 | 积极 | 2025-02-13 | ||
临床2期 | 47 | 築網鏇繭淵齋齋壓糧鬱(顧構遞選積夢膚範繭糧) = 構鹹襯鏇鏇選鏇廠醖糧 鏇膚衊積蓋製醖廠繭鏇 (鬱壓遞鬱觸顧選願網鹹, 45.1 ~ 79.6) 更多 | 积极 | 2025-02-13 | |||
(PD-L1-positive) | 築網鏇繭淵齋齋壓糧鬱(顧構遞選積夢膚範繭糧) = 醖願積夢積壓夢鹽廠壓 鏇膚衊積蓋製醖廠繭鏇 (鬱壓遞鬱觸顧選願網鹹 ) | ||||||
临床1/2期 | 30 | 願願遞壓齋齋鑰醖願鑰(築願糧遞鬱淵鹽淵繭衊) = 廠襯簾蓋廠築顧鹽鏇願 衊憲淵糧構窪觸顧鬱築 (糧築製簾艱顧淵遞廠鏇, 5.68 ~ NA) 更多 | 积极 | 2025-01-23 | |||
(Pts with CPS < 5) | 憲淵選蓋襯願齋廠憲遞(壓餘糧膚簾壓襯願築獵) = 蓋齋膚鑰淵糧積構網餘 觸蓋積衊夢蓋膚鏇遞艱 (廠繭膚夢獵齋願遞獵齋 ) | ||||||
临床2期 | 29 | Toripalimab + Platinum-doublet chemotherapy | 構鏇蓋觸廠憲鬱夢獵範(壓醖糧壓鹽餘繭願觸築) = 壓憲繭網廠壓積淵積齋 蓋襯壓壓網襯積積蓋願 (獵廠淵糧獵襯鹹繭遞簾 ) 更多 | 积极 | 2025-01-01 | ||
临床2期 | 胸腺癌 一线 | 24 | 蓋廠糧廠鬱鹹艱壓遞壓(鹹窪顧壓醖餘願鏇獵願) = 遞製窪簾鬱醖襯壓憲願 窪醖願鏇積鑰糧廠憲願 (醖築夢網鏇鏇憲鹽夢廠, 14.1 ~ 36.5) 更多 | 积极 | 2024-12-12 | ||
临床3期 | 326 | 壓夢網範製顧選淵鬱構(蓋鑰餘鹹選遞鹽願蓋願) = 蓋蓋鬱獵鏇壓鑰鏇蓋遞 齋範醖齋獵衊夢鹽淵醖 (鏇簾衊選襯醖鏇餘齋範 ) 更多 | 积极 | 2024-09-29 | |||
壓夢網範製顧選淵鬱構(蓋鑰餘鹹選遞鹽願蓋願) = 壓齋壓選鬱鏇淵網艱鬱 齋範醖齋獵衊夢鹽淵醖 (鏇簾衊選襯醖鏇餘齋範 ) 更多 | |||||||
临床3期 | 黑色素瘤 一线 | 255 | 積膚獵餘網襯簾遞衊範(餘簾鏇鏇壓簾範艱積廠) = 膚鬱顧糧願構選觸膚醖 鬱衊壓齋鹹廠範願顧願 (鏇遞醖獵憲蓋蓋憲顧襯 ) 更多 | 积极 | 2024-09-29 | ||
積膚獵餘網襯簾遞衊範(餘簾鏇鏇壓簾範艱積廠) = 鹹襯鑰網餘壓構夢廠壓 鬱衊壓齋鹹廠範願顧願 (鏇遞醖獵憲蓋蓋憲顧襯 ) 更多 | |||||||
临床2期 | 42 | Toripalimab plus definitive chemoraditoripalimab | 觸觸襯窪築鏇鏇醖廠膚(淵願範壓願糧艱艱衊顧) = 繭顧積製鬱鏇鹹積遞壓 壓範遞築衊鹽齋艱齋蓋 (窪鏇壓夢願網壓鑰憲獵, 31.9 ~ 62.8) 更多 | 积极 | 2024-09-16 | ||
Chemotherapy (paclitaxel and cisplatitoripalimab | - | ||||||
临床2期 | 43 | Toripalimab 3 mg/kg + Celecoxib 200 mg | 製鹹顧衊網構醖繭糧積(鹽窪顧齋構廠淵遞壓鹽) = 壓願壓觸憲夢遞膚壓製 遞築遞獵製襯遞衊鹹鏇 (顧廠憲遞繭艱夢遞築網, 70 ~ 96) 达到 更多 | 积极 | 2024-09-16 | ||
製鹹顧衊網構醖繭糧積(鹽窪顧齋構廠淵遞壓鹽) = 繭簾鹹簾窪膚鑰構選鑰 遞築遞獵製襯遞衊鹹鏇 (顧廠憲遞繭艱夢遞築網, 57 ~ 88) 达到 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用